RT Journal Article
SR Electronic
T1 Analysis of respiratory and systemic immune responses in COVID-19 reveals mechanisms of disease pathogenesis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.15.20208041
DO 10.1101/2020.10.15.20208041
A1 Szabo, Peter A.
A1 Dogra, Pranay
A1 Gray, Joshua I.
A1 Wells, Steven B.
A1 Connors, Thomas J.
A1 Weisberg, Stuart P.
A1 Krupska, Izabela
A1 Matsumoto, Rei
A1 Poon, Maya M.L.
A1 Idzikowski, Emma
A1 Morris, Sinead E.
A1 Pasin, Chloé
A1 Yates, Andrew J.
A1 Ku, Amy
A1 Chait, Michael
A1 Davis-Porada, Julia
A1 Zhou, Jing
A1 Steinle, Matthew
A1 Mackay, Sean
A1 Saqi, Anjali
A1 Baldwin, Matthew
A1 Sims, Peter A.
A1 Farber, Donna L.
YR 2020
UL http://medrxiv.org/content/early/2020/10/18/2020.10.15.20208041.abstract
AB Immune responses to respiratory viruses like SARS-CoV-2 originate and function in the lung, yet assessments of human immunity are often limited to blood. Here, we conducted longitudinal, high-dimensional profiling of paired airway and blood samples from patients with severe COVID-19, revealing immune processes in the respiratory tract linked to disease pathogenesis. Survival from severe disease was associated with increased CD4+T cells and decreased monocyte/macrophage frequencies in the airway, but not in blood. Airway T cells and macrophages exhibited tissue-resident phenotypes and activation signatures, including high level expression and secretion of monocyte chemoattractants CCL2 and CCL3 by airway macrophages. By contrast, monocytes in blood expressed the CCL2-receptor CCR2 and aberrant CD163+ and immature phenotypes. Extensive accumulation of CD163+monocyte/macrophages within alveolar spaces in COVID-19 lung autopsies suggested recruitment from circulation. Our findings provide evidence that COVID-19 pathogenesis is driven by respiratory immunity, and rationale for site-specific treatment and prevention strategies.Competing Interest StatementJing Zhou, Matthew Steinle, and Sean Mackay have competing interests with IsoPlexis. The remaining authors declare no competing interests.Funding StatementThis work was supported by NIH grants AI128949 and AI06697 awarded to D.L.Farber and a Chan Zuckerberg Initiative COVID-19 grant awarded to D.L.Farber and P.A.Sims, and an R01AI093870 awarded to A.J.Y.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All human subjects research reported in this study was approved by the Columbia University institutional Review Board (IRB).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe scRNA-seq data for each sample including count matrices, normalized counts, metadata, cell annotations, and UMAP embeddings are available on the COVID-19 Cell Atlas along with interactive visualizations with the url provided below. https://www.covid19cellatlas.org/index.patient.html